Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolution of structural rearrangements in prostate cancer intracranial metastases.
Khani F, Hooper WF, Wang X, Chu TR, Shah M, Winterkorn L, Sigouros M, Conteduca V, Pisapia D, Wobker S, Walker S, Graff JN, Robinson B, Mosquera JM, Sboner A, Elemento O, Robine N, Beltran H. Khani F, et al. Among authors: graff jn. NPJ Precis Oncol. 2023 Sep 13;7(1):91. doi: 10.1038/s41698-023-00435-3. NPJ Precis Oncol. 2023. PMID: 37704749 Free PMC article.
Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases.
Khani F, Hooper WF, Wang X, Chu TR, Shah M, Winterkorn L, Sigouros M, Conteduca V, Pisapia D, Wobker S, Walker S, Graff JN, Robinson B, Mosquera JM, Sboner A, Elemento O, Robine N, Beltran H. Khani F, et al. Among authors: graff jn. NPJ Precis Oncol. 2023 Nov 2;7(1):113. doi: 10.1038/s41698-023-00469-7. NPJ Precis Oncol. 2023. PMID: 37919447 Free PMC article. No abstract available.
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.
Graff JN, Burotto M, Fong PC, Pook DW, Zurawski B, Manneh Kopp R, Salinas J, Bylow KA, Kramer G, Ratta R, Kwiatkowski M, Retz M, Kwak C, Arranz Arija JA, Gurney H, Matsubara N, Villanueva L, Todenhöfer T, Liang LW, Todoric J, Imai K, Stenzl A; KEYNOTE-641 Investigators. Graff JN, et al. Ann Oncol. 2025 Aug;36(8):976-987. doi: 10.1016/j.annonc.2025.05.007. Epub 2025 May 16. Ann Oncol. 2025. PMID: 40383193 Free article. Clinical Trial.
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.
Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES. Graff JN, et al. Prostate Cancer Prostatic Dis. 2025 Jun;28(2):411-418. doi: 10.1038/s41391-024-00865-5. Epub 2024 Aug 12. Prostate Cancer Prostatic Dis. 2025. PMID: 39134652 Clinical Trial.
Elevated Tumor-Associated Androgen Receptor Activity Correlates with Poor Immune Infiltration and Immunotherapy Response across Cancer Types.
Hu YM, Zhao F, Graff JN, Chen C, Zhang Y, Stommel JM, Lee J, Zangirolani GM, Rose J, Thomas GV, Wu H, Kardosh A, Mills GB, Alumkal JJ, Moran AE, Xia Z. Hu YM, et al. Among authors: graff jn. Cancer Res Commun. 2026 Jan 1;6(1):17-35. doi: 10.1158/2767-9764.CRC-25-0409. Epub 2025 Nov 26. Cancer Res Commun. 2026. PMID: 41486951 Free PMC article.
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
Einstein DJ, Abel ML, Aragon-Ching JB, Arlen PM, Autio KA, Bilusic M, Carducci MA, Choyke PL, Citrin DE, Figg WD, Graff JN, Gulley JL, Halabi S, Karzai F, Lindenberg L, Markowski MC, Marshall CH, McNeel DG, Mena E, Moon H, Pachynski RK, Paller CJ, Patel KR, Posadas EM, Pienta KJ, Regan MM, Sena LA, Walmsley CS, Wei XX, Yu EY, Tran PT, Madan RA. Einstein DJ, et al. Among authors: graff jn. J Clin Oncol. 2025 Dec;43(34):3672-3683. doi: 10.1200/JCO-25-01693. Epub 2025 Oct 23. J Clin Oncol. 2025. PMID: 41129763
73 results